Aigen Investment Management LP Increases Position in Kenvue Inc. $KVUE

Aigen Investment Management LP increased its stake in Kenvue Inc. (NYSE:KVUE) by 58.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 179,042 shares of the company’s stock after acquiring an additional 66,052 shares during the quarter. Kenvue accounts for 0.7% of Aigen Investment Management LP’s portfolio, making the stock its 22nd largest position. Aigen Investment Management LP’s holdings in Kenvue were worth $3,088,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also made changes to their positions in the stock. Aberdeen Group plc increased its holdings in Kenvue by 84.1% during the 3rd quarter. Aberdeen Group plc now owns 1,411,380 shares of the company’s stock valued at $22,914,000 after acquiring an additional 644,930 shares in the last quarter. Oak Thistle LLC purchased a new position in Kenvue during the 4th quarter valued at about $1,563,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Kenvue by 25.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 410,874 shares of the company’s stock valued at $7,088,000 after acquiring an additional 84,219 shares in the last quarter. SG Americas Securities LLC increased its holdings in Kenvue by 3,889.9% during the 4th quarter. SG Americas Securities LLC now owns 3,075,723 shares of the company’s stock valued at $53,056,000 after acquiring an additional 2,998,635 shares in the last quarter. Finally, ICICI Prudential Asset Management Co Ltd increased its holdings in Kenvue by 137.9% during the 3rd quarter. ICICI Prudential Asset Management Co Ltd now owns 452,060 shares of the company’s stock valued at $7,337,000 after acquiring an additional 262,000 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Price Performance

KVUE opened at $18.13 on Friday. The company’s 50 day simple moving average is $17.43 and its 200 day simple moving average is $17.53. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.70 and a current ratio of 0.98. Kenvue Inc. has a 1 year low of $14.02 and a 1 year high of $22.87. The stock has a market capitalization of $34.80 billion, a PE ratio of 21.32, a P/E/G ratio of 1.38 and a beta of 0.54.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, May 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The business had revenue of $3.91 billion for the quarter, compared to analysts’ expectations of $3.84 billion. During the same period last year, the company earned $0.24 earnings per share. The company’s quarterly revenue was up 4.5% on a year-over-year basis. As a group, sell-side analysts expect that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a $0.2075 dividend. The ex-dividend date of this dividend was Wednesday, May 13th. This represents a $0.83 annualized dividend and a dividend yield of 4.6%. Kenvue’s dividend payout ratio (DPR) is currently 97.65%.

Insider Activity

In related news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 1.59% of the company’s stock.

Wall Street Analysts Forecast Growth

KVUE has been the topic of several analyst reports. Argus raised shares of Kenvue to a “hold” rating in a research note on Friday, March 6th. Weiss Ratings cut shares of Kenvue from a “hold (c)” rating to a “hold (c-)” rating in a research note on Friday, May 29th. Canaccord Genuity Group raised their price target on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. UBS Group decreased their price target on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Finally, Barclays decreased their price target on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.